The weight-loss drug gold rush is getting larger
More drug companies are racing to join what's been a two-horse race to make blockbuster obesity drugs, snapping up smaller biotechs and vying for a market that could be worth tens of billions in less than a decade. Why it matters: GLP-1 agonists like Novo Nordisk's Wegovy and Ozempic have soared…#glp1 #novonordisk #wegovyandozempic #medicare #zuercherkantonalbank #roche #carmottherapeutics #obese #carmot #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
Cramer says the growing popularity of weight loss drugs brings new investing opportunities
CNBC's Jim Cramer on Monday said the increasing popularity of GLP-1 drugs — medications used to treat diabetes and obesity — has created some new investing opportunities. According to Cramer, Wall Street feared the effects of these drugs on the market during the fall. Investors soured on companies…#jimcramer #glp1 #cramerwallstreet #elililly #novonordisk #jacobssolutions #chipbergh (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
Brits are eating fewer vegetables than at any time in the last 50 years as grocery costs spiral, analysis finds
The figures come on the back of reports that vegetable prices are rising ahead of Christmas , plus new research showing shocking obesity levels are putting a huge strain on the NHS. (Source: the Mail online | Health)
Source: the Mail online | Health - December 5, 2023 Category: Consumer Health News Source Type: news
Sobering charts lay bare the reality of UK's ever-worsening obesity crisis as shock analysis claims nation's bulging waistline is costing £100billion a year
Britain is losing the battle against the bulge as fresh estimates put the cost of obesity and being overweight to the public, the NHS, and wider society at an colossal £98 billion per year. (Source: the Mail online | Health)
Source: the Mail online | Health - December 4, 2023 Category: Consumer Health News Source Type: news
Health Care Roundup: Market Talk
1025 ET – Recent developments in the obesity space should buoy the attractiveness of Viking Therapeutics to big pharma, analysts at William Blair say. In a research note, Andy Hsieh and Alexandra Ramsey say Viking is in an enviable position with a highly competitive GLP-1/GIP dual agonist program…#vikingtherapeutics #williamblair #andyhsieh #alexandraramsey #glp1 #phase2 #roche #carmottherapeutics #novonordisk #elililly (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news
Roche joins race for obesity drugs with $2.7 billion Carmot deal
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights Dec 4 (Reuters) - Roche (ROG.S) agreed to take over unlisted obesity drug developer Carmot Therapeutics (CRMO.O) for $2.7 billion upfront,…#roche #basel #switzerland #carmottherapeutics #novonordisk #elililly #glp1 #lilly #carmot #teresagraham (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news
Genentech parent Roche to buy obesity-focused East Bay drug maker Carmot Therapeutics for potential $3.1 billion
Carmot last month filed to go public. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 4, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
US Obesity Docs Expect Zepbound to Show Heart Benefit US Obesity Docs Expect Zepbound to Show Heart Benefit
Some leading US obesity specialists say they expect Eli Lilly ’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D
(MedPage Today) -- Pemvidutide (2.4 mg), an investigational GLP-1/glucagon dual receptor agonist, helped people with obesity achieve an average 15.6% weight loss after 48 weeks in the phase II MOMENTUM trial, developer Altimmune announced.
Meanwhile... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 4, 2023 Category: Endocrinology Source Type: news
Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects
Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Being overweight and obese increases suicide risk, the severity of depression, and the inflammatory response in adolescents with major depressive disorders - Ninla-Aesong P, Puangsri P, Kietdumrongwong P, Jongkrijak H, Noipha K.
BACKGROUND: There is a bidirectional relationship between obesity and depression. We investigated whether the coexistence of obesity and depression increases the risk of having severe depression and a high suicide risk in adolescents with major depressive ... (Source: SafetyLit)
Source: SafetyLit - December 4, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Investor Update - December 4, 2023 Category: Pharmaceuticals Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Media News - December 4, 2023 Category: Pharmaceuticals Source Type: news
Roche to buy Carmot Therapeutics for up to $3.1bn as obesity drug market booms
Swiss pharma company expects deal to close in first quarter of 2024 (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2023 Category: Consumer Health News Source Type: news
Britain's obesity crisis is costing UK nearly £100billion a year and will ruin Rishi Sunak's plans to get the sick back to work, analysis suggests
The country's obesity problem is making the nation 'sick and impoverished', the Government's former food adviser Henry Dimbleby says, with two-thirds of Brits overweight. (Source: the Mail online | Health)
Source: the Mail online | Health - December 4, 2023 Category: Consumer Health News Source Type: news
